---
title: "J.P. Morgan Remains a Sell on Intellia Therapeutics (NTLA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286414339.md"
description: "J.P. Morgan analyst Brian Cheng has maintained a Sell rating on Intellia Therapeutics (NTLA) with a price target of $8.00, while the shares closed at $14.28. Cheng, a 4-star analyst, has an average return of 6.7% and a 52.55% success rate. Goldman Sachs also issued a Sell rating on Intellia, while Morgan Stanley maintained a Hold rating."
datetime: "2026-05-14T12:09:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286414339.md)
  - [en](https://longbridge.com/en/news/286414339.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286414339.md)
---

# J.P. Morgan Remains a Sell on Intellia Therapeutics (NTLA)

J.P. Morgan analyst Brian Cheng maintained a Sell rating on Intellia Therapeutics yesterday and set a price target of $8.00. The company’s shares closed yesterday at $14.28.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Cheng is a 4-star analyst with an average return of 6.7% and a 52.55% success rate. Cheng covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Revolution Medicines, and Protara Therapeutics.

In addition to J.P. Morgan, Intellia Therapeutics also received a Sell from Goldman Sachs’s Salveen Richter in a report issued on May 11. However, yesterday, Morgan Stanley maintained a Hold rating on Intellia Therapeutics (NASDAQ: NTLA).

### Related Stocks

- [NTLA.US](https://longbridge.com/en/quote/NTLA.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [HELX.US](https://longbridge.com/en/quote/HELX.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [WDNA.US](https://longbridge.com/en/quote/WDNA.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [PTGX.US](https://longbridge.com/en/quote/PTGX.US.md)
- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)
- [TARA.US](https://longbridge.com/en/quote/TARA.US.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)
- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [ARK Invest’s NTLA Buy Puts Dilution And CRISPR Progress In Focus](https://longbridge.com/en/news/285354302.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)